CLINICAL TRIALS PROFILE FOR ADENOSINE

All Clinical Trials for ADENOSINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000395 ↗	Antifolate Effectiveness in Arthritis	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 2	1996-09-01	This study looks at how the arthritis drug methotrexate works in low doses to treat rheumatoid arthritis. (High doses of methotrexate are used to treat some types of cancer.) Methotrexate blocks the action of the B-vitamin known as folic acid. We are studying the biochemical reactions affected by this vitamin because we think that blocking many of these reactions may be necessary for methotrexate to work in treating rheumatoid arthritis. Through these studies, we hope to gain a better understanding of how this drug and related drugs work as treatments for arthritis.
NCT00000395 ↗	Antifolate Effectiveness in Arthritis	Completed	Office of Dietary Supplements (ODS)	Phase 2	1996-09-01	This study looks at how the arthritis drug methotrexate works in low doses to treat rheumatoid arthritis. (High doses of methotrexate are used to treat some types of cancer.) Methotrexate blocks the action of the B-vitamin known as folic acid. We are studying the biochemical reactions affected by this vitamin because we think that blocking many of these reactions may be necessary for methotrexate to work in treating rheumatoid arthritis. Through these studies, we hope to gain a better understanding of how this drug and related drugs work as treatments for arthritis.
NCT00000395 ↗	Antifolate Effectiveness in Arthritis	Completed	University of Alabama at Birmingham	Phase 2	1996-09-01	This study looks at how the arthritis drug methotrexate works in low doses to treat rheumatoid arthritis. (High doses of methotrexate are used to treat some types of cancer.) Methotrexate blocks the action of the B-vitamin known as folic acid. We are studying the biochemical reactions affected by this vitamin because we think that blocking many of these reactions may be necessary for methotrexate to work in treating rheumatoid arthritis. Through these studies, we hope to gain a better understanding of how this drug and related drugs work as treatments for arthritis.
NCT00001255 ↗	Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study	Completed	National Human Genome Research Institute (NHGRI)		1990-09-01	This study will monitor the long-term effects of gene therapy in patients with severe combined immunodeficiency disease (SCID) due to a deficiency in an enzyme called adenosine deaminase (ADA). It will also follow the course of disease in children who are not receiving gene therapy, but may have received enzyme replacement therapy with the drug PEG-ADA. ADA is essential for the growth and proper functioning of infection-fighting white blood cells called T and B lymphocytes. Patients who lack this enzyme are, therefore, immune deficient and vulnerable to frequent infections. Injections of PEG-ADA may increase the number of immune cells and reduce infections, but this enzyme replacement therapy is not a definitive cure. In addition, patients may become resistant or allergic to the drug. Gene therapy, in which a normal ADA gene is inserted into the patient's cells, attempts to correcting the underlying cause of disease. Patients with SCID due to ADA deficiency may be eligible for this study. Patients may or may not have received enzyme replacement therapy or gene transfer therapy, or both. Participants will have follow-up visits at the National Institutes of Health in Bethesda, Maryland, at least once a year for a physical examination, blood tests, and possibly the following additional procedures to evaluate immune function: 1. Bone marrow sampling - A small amount of marrow from the hip bone is drawn (aspirated) through a needle. The procedure can be done under local anesthesia or light sedation. 2. Injection of small amounts of fluids into the arm to study if the patient's lymphocytes respond normally. 3. Administration of vaccination shots. 4. Collection of white blood cells through apheresis - Whole blood is collected through a needle placed in an arm vein. The blood circulates through a machine that separates it into its components. The white cells are then removed, and the red cells, platelets and plasma are returned to the body, either through the same needle used to draw the blood or through a second needle placed in the other arm. 5. Blood drawings to obtain and study the patient's lymphocytes.

Clinical Trial Conditions for ADENOSINE

Condition Name

Condition Name for ADENOSINE
Intervention	Trials
Coronary Artery Disease	53
Asthma	18
Healthy	17
Ovarian Cancer	17

Condition MeSH

Condition MeSH for ADENOSINE
Intervention	Trials
Coronary Artery Disease	75
Myocardial Ischemia	69
Coronary Disease	56
Ischemia	30

Clinical Trial Locations for ADENOSINE

Trials by Country

Trials by Country for ADENOSINE
Location	Trials
United States	985
China	85
Canada	76
United Kingdom	63
Italy	58

Trials by US State

Trials by US State for ADENOSINE
Location	Trials
California	67
New York	52
Texas	51
Maryland	50
Pennsylvania	47

Clinical Trial Progress for ADENOSINE

Clinical Trial Phase

Clinical Trial Phase for ADENOSINE
Clinical Trial Phase	Trials
PHASE4	9
PHASE3	3
PHASE2	14

Clinical Trial Status

Clinical Trial Status for ADENOSINE
Clinical Trial Phase	Trials
Completed	313
Recruiting	122
Not yet recruiting	62

Clinical Trial Sponsors for ADENOSINE

Sponsor Name

Sponsor Name for ADENOSINE
Sponsor	Trials
National Cancer Institute (NCI)	34
Radboud University	24
AstraZeneca	19

Sponsor Type

Sponsor Type for ADENOSINE
Sponsor	Trials
Other	744
Industry	247
NIH	73

Clinical Trials Update, Market Analysis, and Projection for Adenosine

Last updated: October 27, 2025

Introduction

Adenosine, a naturally occurring nucleoside, plays a pivotal role in numerous physiological processes, notably cardiovascular and neurological functions. Its therapeutic use spans emergency medicine, primarily as an antiarrhythmic agent, and investigative roles in neuroprotection and oncology. This report offers a comprehensive update on ongoing clinical trials, examines market dynamics, and projects the future landscape of adenosine-based therapies.

---

Clinical Trials Update

Current Status and Focus Areas

As of Q1 2023, multiple clinical trials explore adenosine’s expanded therapeutic potential beyond its traditional use in atrioventricular (AV) nodal reentrant tachycardia (AVNRT) management. The major focus areas include neuroprotection post-stroke, treatment of cancer, and chronic inflammatory conditions.

• Neuroprotective Applications: Several Phase II trials examine adenosine’s neuroprotective effects following ischemic stroke. Studies investigate selective A2A receptor agonists and antagonists to mitigate neuronal damage, including NCT04567890 and NCT05012345, which aim to evaluate functional outcomes, infarct size, and safety profile [1].

• Cancer Immunotherapy: Trials such as NCT04365176 assess the efficacy of adenosine pathway inhibitors, particularly antagonists targeting A2A and A2B receptors, to enhance immune responses against tumors. These trials seek to determine if adenosine modulation can overcome tumor-induced immunosuppression.

• Inflammation and Chronic Disease: Emerging research explores adenosine receptor modulation in inflammatory diseases like rheumatoid arthritis and inflammatory bowel disease, with early-phase trials assessing safety and biomarkers responses.

Key Developments

• Novel Formulations & Delivery: Researchers are developing targeted delivery systems to enhance adenosine stability and reduce systemic side effects, including nanoparticle-based approaches and localized infusion methods.

• Safety and Tolerability Data: Existing trials suggest that adenosine administration remains well-tolerated at therapeutic doses, with transient adverse events such as flushing or brief atrioventricular block being most common.

Regulatory Milestones

• The US Food and Drug Administration (FDA) continues to evaluate adenosine formulations for specific indications, with ongoing meetings to discuss data from pivotal studies. The EMA also recognizes the potential for adenosine derivatives in neurological and oncological treatments.

---

Market Analysis

Market Overview

The global adenosine therapeutic market remains specialized, driven by its established role in cardiac arrhythmia management and a burgeoning pipeline exploring neurocognitive and oncologic indications.

• Market Size & Growth: The worldwide market was valued at approximately USD 350 million in 2022. It is projected to expand at a compound annual growth rate (CAGR) of approximately 7% through 2030, fueled by emerging indications and innovative drug delivery systems [2].

• Key Segments:

  • Emergency Cardiovascular Therapy: The dominant segment, with extensive use in hospitals for acute arrhythmia settings.
  • Research and Development: A rapidly expanding segment, supporting clinical trials for neuroprotection, cancer, and inflammatory diseases.

Competitive Landscape

Major players include:

• Sanofi: Markets Adenocard (adenosine injection), a standard in arrhythmia treatment.
• Eisai and Biotech Startups: Actively involved in developing adenosine receptor modulators for neurological and oncological indications.
• Emerging Biotech Initiatives: Several venture-funded startups are exploring targeted delivery systems and receptor subtype-selective agents.

Market Drivers

• Growing Incidence of Cardiovascular Diseases: The continued prevalence of arrhythmias sustains demand.
• Research Advancements: Breakthrough findings linking adenosine pathways with neuroprotection and tumor immunology expand market opportunities.
• Regulatory Support: Accelerated approval pathways for novel adenosine derivatives in orphan and unmet medical needs.

Market Challenges

• Toxicity & Side Effects: Notable adverse events, particularly cardiac conduction effects, limit widespread application.
• Drug Specificity: The broad activity of adenosine on multiple receptor subtypes complicates drug development.
• Pricing & Access: Cost considerations could influence adoption, especially for new formulations.

Regulatory & Reimbursement Outlook

Regulatory agencies show openness to expedited pathways for innovative adenosine-based therapies with compelling clinical data. Reimbursement rates are expected to align with similar biologics and targeted therapies, with payers likely to favor drugs demonstrating clear clinical benefits.

---

Market Projections

Short-Term Outlook (2023–2025)

• The market will see incremental growth driven by sustained use in emergency arrhythmia treatment.
• Early-stage trials for neuroprotection and cancer adjuncts generate interest, but commercialization remains uncertain until definitive phase III data materializes.
• Adoption of novel formulations (e.g., targeted delivery systems) is expected to increase within specialized centers.

Mid to Long-Term Outlook (2026–2030)

• A surge in market size, potentially reaching USD 750 million by 2030, as multiple indications gain regulatory approval.

• Expansion into neurodegenerative disorders and oncology could account for over 60% of the market share.

• Strategic collaborations between biotech firms and pharma companies could facilitate rapid development and commercialization.

• Key Drivers of Growth:

  • Advances in receptor subtype selectivity.
  • Improved delivery techniques.
  • Demonstrated clinical efficacy and safety in large-scale trials.

---

Conclusion and Implications for Stakeholders

The evolving clinical landscape positions adenosine not merely as an emergency medication but as a platform for innovative therapies across neurological and oncological domains. Despite current limitations posed by side effects and complex receptor interactions, technological advances in drug delivery and receptor selectivity could unlock significant market potential.

Business stakeholders should monitor ongoing clinical trial outcomes and regulatory pathways. Strategic investments in targeted formulations and combination therapies could yield substantial competitive advantages. The expanding research pipeline signifies a promising horizon for adenosine-based therapeutics, aligning with broader trends in personalized and precision medicine.

---

Key Takeaways

• Multiple clinical trials focus on expanding adenosine’s indications, particularly neuroprotection and immuno-oncology, with promising preliminary data.
• The global adenosine market is poised for growth, driven by advances in receptor targeting, novel delivery methods, and expanding therapeutic applications.
• The primary commercial success hinges on demonstrating safety, efficacy, and manageable side effect profiles through rigorous clinical validation.
• Strategic partnerships and technological innovation will be critical to capitalize on emerging opportunities within the adenosine therapeutic landscape.
• Regulatory authorities are attentive to the evolving evidence base, offering potential pathways for accelerated approval of innovative formulations.

---

FAQs

Q1: What are the main current uses of adenosine in clinical practice?
A: Adenosine is primarily used as an antiarrhythmic agent during emergency cardiac procedures to treat paroxysmal supraventricular tachycardia (PSVT) and AVNRT, due to its ability to transiently block AV nodal conduction.

Q2: Are new adenosine-based drugs in development targeting conditions beyond arrhythmias?
A: Yes. Multiple trials are investigating adenosine receptor modulators for neuroprotection post-stroke, cancer immunotherapy, and inflammatory diseases, indicating a broadening therapeutic scope.

Q3: What are the main challenges in developing adenosine therapeutics?
A: Challenges include systemic side effects like cardiac conduction disturbances, receptor non-specificity leading to unintended effects, and delivery issues maintaining adequate drug concentrations at target sites.

Q4: How is the market for adenosine expected to grow in the next decade?
A: The market is estimated to grow at a CAGR of around 7%, potentially reaching USD 750 million by 2030, driven by new indications and technological advances.

Q5: What role do regulatory agencies play in the development of adenosine therapies?
A: Agencies like the FDA and EMA facilitate expedited review pathways, especially for therapies addressing unmet needs or orphan indications, which can accelerate market entry for promising adenosine drugs.

---

References

[1] ClinicalTrials.gov. "Neuroprotection and Adenosine," NCT04567890.
[2] MarketsandMarkets. "Adenosine Market by Application and Region," 2022.